Comparison of 3 Different Density Levobupivacaine Solutions + Fentanyl for Spinal Anaesthesia for Caesarean Delivery.

NCT ID: NCT03956303

Last Updated: 2019-05-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-30

Study Completion Date

2016-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigator's aim is to compare the efficacy of 3 levobupivacaine solutions with different density on spinal anesthesia for caesarean delivery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients scheduled for elective caesarean delivery were separated into 4 groups. Spinal anesthesia was performed with one of the following regimens.

Group 1: Levobupivacaine 8 mg + 20 mcg Fentanyl Group 2: Levobupivacaine 8 mg + 20 mcg Fentanyl + 40 mg Dextrose Group 3: Levobupivacaine 8 mg + 20 mcg Fentanyl + 60 mg Dextrose Group 4: Levobupivacaine 8 mg + 20 mcg Fentanyl + 80 mg Dextrose After anesthesia induction motor block was evaluated via bromage scale and sensory block via pinprick test every 3 minutes for the first 15 minutes, and every 5 minutes up to 60 minutes. Maximum sensory block level, time to reach maximum block level, time needed to achieve T10 sensory level were recorded.

Baby delivery time, and operation duration were also recorded. Time to two segment regression of maximum sensory block, motor block recovery time and time to S2 regression of sensory block will be recorded.

Hemodynamic data, nausea vomiting, were also recorded throughout surgery at the same evaluation periods and postoperative period.

The surgeon will also evaluate the abdominal relaxation surgical block quality as good, medium and poor.

The patient will evaluate spinal block analgesia quality as good, medium or poor.

Pain scores are going to be evaluated by VAS at the beginning, uterine incision and during abdominal closure. Time for first analgesic requirement and postoperative pain is also going to be evaluated by VAS.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anesthesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Plain Levobupivacaine (Chirocaine (% 0.5)

Levobupivacaine 8 mg (Chirocaine (% 0.5)) + 20 mcg fentanyl Chirocaine Plain

Group Type ACTIVE_COMPARATOR

Chirocaine %0.5

Intervention Type DRUG

Levobupivacaine 8 mg Chirocaine (% 0.5) +20 mcg fentanyl

Levobupivacaine (Chirocaine % 0,75) + dextrose 40

Levobupivacaine 8 mg (Chirocaine % 0,75) + 20 mcg fentanyl + dextrose 40 Chirocaine Heavy 40

Group Type ACTIVE_COMPARATOR

Chirocaine Heavy 40

Intervention Type DRUG

Chirocaine (%0.75) + Dextrose 40 mg+20 mcg fentanyl

Levobupivacaine (Chirocaine % 0,75) + dextrose 60

Levobupivacaine 8 mg (Chirocaine % 0,75) + 20 mcg fentanyl + dextrose 60 Chirocaine Heavy 60

Group Type ACTIVE_COMPARATOR

Chirocaine Heavy 60

Intervention Type DRUG

Chirocaine (%0.75) + Dextrose 60 mg+20 mcg fentanyl

Levobupivacaine (Chirocaine % 0,75) + dextrose 80

Levobupivacaine 8 mg (Chirocaine % 0,75) + 20 mcg fentanyl + dextrose 80 Chirocaine Heavy 80

Group Type ACTIVE_COMPARATOR

Chirocaine Heavy 80

Intervention Type DRUG

Chirocaine (%0.75) + Dextrose 80 mg+20 mcg fentanyl

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Chirocaine %0.5

Levobupivacaine 8 mg Chirocaine (% 0.5) +20 mcg fentanyl

Intervention Type DRUG

Chirocaine Heavy 40

Chirocaine (%0.75) + Dextrose 40 mg+20 mcg fentanyl

Intervention Type DRUG

Chirocaine Heavy 60

Chirocaine (%0.75) + Dextrose 60 mg+20 mcg fentanyl

Intervention Type DRUG

Chirocaine Heavy 80

Chirocaine (%0.75) + Dextrose 80 mg+20 mcg fentanyl

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Plain levobupivacaine Group 1 levobupivacaine heavy 40 Group 2 levobupivacaine heavy 60 Group 3 levobupivacaine heavy 80 Group 4

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ASA I-II
* Pregnancy at Term
* Scheduled for elective caesarean delivery

Exclusion Criteria

* contraindication for spinal anesthesia
* drug allergy
* pregnancy related disorders (hypertension, placenta previa, fetal problems)
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Balikesir University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ozlem Sagir, MD

Associated Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ozlem Sagir, Assist. Prof

Role: STUDY_DIRECTOR

Balikesir University School of Medicine Department of Anesthesia and Reanimation

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

osagir2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.